Share-based Payment Arrangement, Expense of Cidara Therapeutics, Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cidara Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
  • Cidara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,171,000, a 322% increase year-over-year.
  • Cidara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $9,525,000, a 209% increase year-over-year.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,907,000, a 28% increase from 2023.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,061,000, a 17% decline from 2022.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,705,000, a 7.7% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cidara Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,525,000 $3,171,000 +$2,420,000 +322% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $7,105,000 $2,955,000 +$2,252,000 +320% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $4,853,000 $1,741,000 +$946,000 +119% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $3,907,000 $1,658,000 +$828,000 +100% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $3,079,000 $751,000 -$45,000 -5.7% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $3,124,000 $703,000 -$92,000 -12% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $3,216,000 $795,000 +$155,000 +24% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $3,061,000 $830,000 +$157,000 +23% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $2,904,000 $796,000 -$46,000 -5.5% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $2,950,000 $795,000 -$57,000 -6.7% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $3,007,000 $640,000 -$698,000 -52% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $3,705,000 $673,000 -$690,000 -51% 01 Oct 2022 31 Dec 2022 10-K 22 Apr 2024 2023 FY
Q3 2022 $4,395,000 $842,000 -$59,000 -6.5% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $4,454,000 $852,000 -$19,000 -2.2% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $4,473,000 $1,338,000 +$459,000 +52% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,014,000 $1,363,000 +$516,000 +61% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $3,498,000 $901,000 -$101,000 -10% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $3,599,000 $871,000 -$124,000 -12% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $3,723,000 $879,000 -$367,000 -29% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $4,090,000 $847,000 -$176,000 -17% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
Q3 2020 $4,266,000 $1,002,000 -$507,000 -34% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $4,773,000 $995,000 -$262,000 -21% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $5,035,000 $1,246,000 -$38,000 -3% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $5,073,000 $1,023,000 -$341,000 -25% 01 Oct 2019 31 Dec 2019 10-K 07 Mar 2022 2021 FY
Q3 2019 $5,414,000 $1,509,000 +$224,000 +17% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $5,190,000 $1,257,000 -$343,000 -21% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $5,533,000 $1,284,000 -$177,000 -12% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $5,710,000 $1,364,000 -$143,000 -9.5% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $5,853,000 $1,285,000 -$270,000 -17% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $6,123,000 $1,600,000 -$1,000 -0.06% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $6,124,000 $1,461,000 +$410,000 +39% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $5,714,000 $1,507,000 +$415,000 +38% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q3 2017 $5,299,000 $1,555,000 +$245,000 +19% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $5,054,000 $1,601,000 +$492,000 +44% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $4,562,000 $1,051,000 +$218,000 +26% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $4,344,000 $1,092,000 +$304,000 +39% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2018 2017 FY
Q3 2016 $4,040,000 $1,310,000 +$544,000 +71% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $3,496,000 $1,109,000 +$269,000 +32% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $3,227,000 $833,000 +$194,000 +30% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $3,033,000 $788,000 +$613,000 +350% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2017 2016 FY
Q3 2015 $2,420,000 $766,000 +$717,000 +1463% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $1,703,000 $840,000 +$834,000 +13900% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $869,000 $639,000 +$637,000 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 $232,000 $175,000 01 Oct 2014 31 Dec 2014 10-K 18 Mar 2016 2015 FY
Q3 2014 $49,000 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015 2015 Q3
Q2 2014 $6,000 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $2,000* 01 Jan 2014 31 Mar 2014 10-Q 21 May 2015 2015 Q1

Cidara Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,907,000 +$846,000 +28% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $3,061,000 -$644,000 -17% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $3,705,000 -$309,000 -7.7% 01 Jan 2022 31 Dec 2022 10-K 22 Apr 2024 2023 FY
2021 $4,014,000 -$76,000 -1.9% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $4,090,000 -$983,000 -19% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
2019 $5,073,000 -$637,000 -11% 01 Jan 2019 31 Dec 2019 10-K 07 Mar 2022 2021 FY
2018 $5,710,000 -$4,000 -0.07% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $5,714,000 +$1,370,000 +32% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2019 2018 FY
2016 $4,344,000 +$1,311,000 +43% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2018 2017 FY
2015 $3,033,000 +$2,801,000 +1207% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2017 2016 FY
2014 $232,000 01 Jan 2014 31 Dec 2014 10-K 18 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.